Overview


According to FutureWise analysis the market for gastrointestinal otc drugs in 2023 is US$ 42.05 billion, and is expected to reach US$ 62.69 billion by 2031 at a CAGR of 5.12%.

Gastrointestinal medicine also is known as organic process or viscus medicines. They affect conditions associated with the epithelial duct, as well as abdomen disorders, liver diseases, and different issues within the systema alimentarium. gi medicine square measure won't treat a spread of conditions, as well as gastritis, purposeful stomach upset, ulcer, and acute stomach flu. they're additionally wont to treat different conditions, like inflammation within the lining of the abdomen and intestines. Gastrointestinal over-the-counter medicine square measure medications that square measure safe and effective to be used by the overall public while not seeking treatment from a caregiver. widespread examples embody pain relievers like Phenaphen (Tylenol) and nonsteroidal anti-inflammatory drugs (Motrin), and cough suppressants like dextromethorphan.

Gastrointestinal over-the-counter medicine square measure medications that may be bought with no doctor's prescription and square measure won't manage regurgitation, constipation, diarrhea, and flatulence. Gastrointestinal over-the-counter medicine square measure used for indications like GERD, vomiting, constipation, diarrhea, and flatulence. a number of the over-the-counter medicine that square measure accessible for the treatment of gi diseases square measure laxatives, anti-flatulent, H2-antagonists, antidiarrheals, PPIs, and anti-emetics. Gastrointestinal over-the-counter medicine square measure medications that may be bought while not a prescription and won’t to treat varied organic process issues like constipation, diarrhea, stomach upset, heartburn, and nausea. These medicine square measure accessible over the counter within the style of tablets, capsules, liquids, or powders. Gastrointestinal over-the-counter medicine square measure used for indications like GERD, vomiting, constipation, diarrhea, and flatulence. a number of the over-the-counter medicine that square measure accessible for the treatment of gi diseases square measure laxatives, anti-flatulent, H2-antagonists, antidiarrheals, PPIs, and anti-emetics.

The gi over-the-counter medicine market is growing at a big rate in the main because of a rise in the patient population. Strategic alliances square measure one the most important trends that may be seen within the gi over-the-counter medicine market and square measure supporting the market to grow at a lot of appreciable rates The major factors that contribute to the expansion of the gi over-the-counter medicine market embody the increasing prevalence of gi diseases, high adoption of over-the-counter medications as they're cost-efficient and convenient to shop for, advancements in R D activities like innovations in medicine, and high demand for self-diagnosis and self-medication. However, factors like tight government laws and inadequate reimbursements provided for gi over-the-counter medicine hinder the market growth. Conversely, growth publically awareness and a rise in care expenditures square measure expected to supply varied opportunities for market growth shortly.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Gastrointestinal OTC Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Gastrointestinal OTC Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Johnson and Johnson
  • GlaxoSmithKline Plc
  • Bayer AG
  • Sanofi
  • Abbott Laboratories
  • Pfizer Inc
  • Prestige Brands Inc
  • Boehringer Ingelheim GmbH
  • Procter and Gamble
  • Purdue Pharma L.P.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product

  • Laxatives
  • Gastrointestinal Cancer Treatments
  • Gastric Acid Reducers
  • Anti-Diarrheal
  • Proton Pump Inhibitors
  • H2 Inhibitors
  • Gastric Acid Neutralizers
  • Bowel Anti-inflammatory
  • Anti-Emetics

By Indication

  • Gastroesophageal Reflux Disease or Heartburn
  • Constipation
  • Diarrhea
  • Motion Sickness
  • Flatulence

By End-User

  • Clinics
  • Pharmacies
  • Hospitals
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Gastrointestinal OTC Drugs Market By Product, By Indication, By End-User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Gastrointestinal OTC Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Gastrointestinal OTC Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Gastrointestinal OTC Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Gastrointestinal OTC Drugs Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Laxatives
        2. Gastrointestinal Cancer Treatments
        3. Gastric Acid Reducers
        4. Anti-Diarrheal
        5. Proton Pump Inhibitors
        6. H2 Inhibitors
        7. Gastric Acid Neutralizers
        8. Bowel Anti-inflammatory
        9. Anti-Emetics

  • 8.   Gastrointestinal OTC Drugs Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Gastroesophageal Reflux Disease or Heartburn
        2. Constipation
        3. Diarrhea
        4. Motion Sickness
        5. Flatulence

  • 9.   Gastrointestinal OTC Drugs Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Clinics
        2. Pharmacies
        3. Hospitals
        4. Others

  • 10.   North America Gastrointestinal OTC Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Gastrointestinal OTC Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Gastrointestinal OTC Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Gastrointestinal OTC Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Johnson and Johnson
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. GlaxoSmithKline Plc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bayer AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Sanofi
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Abbott Laboratories
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Pfizer Inc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Prestige Brands Inc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Boehringer Ingelheim GmbH
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Procter and Gamble
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Purdue Pharma L.P.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients